



## **Intercell AG and Statens Serum Institut join forces with Aeras Global TB Vaccine Foundation for novel Tuberculosis Vaccine**

*Vienna / Copenhagen / Bethesda, June 27, 2005* – Intercell AG and Statens Serum Institut (SSI) announced today that their joint project for the development of a new prophylactic tuberculosis vaccine has gained the support of the Aeras Global TB Vaccine Foundation. Aeras, an organization funded by the Bill and Melinda Gates Foundation, specializes in the development of novel TB vaccines with the aim of controlling the disease in developing countries.

Under the terms of the agreement, Aeras will fund the development of the vaccine and subsequent clinical trials. In return, Aeras will be given a sublicense for the future TB vaccine for a number of developing countries with an urgent medical need and very low living standards. For the rest of the world Intercell and SSI will retain their joint marketing and profit-sharing rights.

The product candidate combines Intercell's proprietary synthetic adjuvant IC31™ with SSI's recombinant tuberculosis antigens. The expanded collaboration continues to evaluate further tuberculosis antigens in combination with Intercell's novel adjuvant technology.

Intercell's CEO, Alexander von Gabain, commented: "We are delighted that our collaboration with Statens Serum Institut on a novel tuberculosis vaccine has now obtained the support of the renowned Aeras Foundation. The new partner will bring substantial funding as well as first-class scientific and pharmaceutical expertise to this project. Furthermore we also like to thank both the Austrian Ministry for Economy and Labour as well as the Vienna Business Agency for supporting this promising project with R&D grants."

### **About Tuberculosis**

Tuberculosis kills two million people each year and the disease is predicted to make a dramatic return to industrialized countries. It is estimated that between 2002 and 2020, approximately one billion people will be newly infected, over 150 million people will get sick, and 36 million will die of TB – if control is not further strengthened.

The current vaccine - BCG - is one of the oldest presently in use throughout the world and has a limited efficacy profile.

### **About Intercell AG**

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylaxis and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology





platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including Sanofi Aventis, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis about to enter Phase III, a vaccine for Hepatitis C undergoing Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: [www.intercell.com](http://www.intercell.com)

#### **Contact Intercell AG:**

Katharina Wieser  
Head of Corporate Communications  
Campus Vienna Biocenter 2 - A-1030 Vienna  
P: +43-1-20620-303  
Mail to: [kwieser@intercell.com](mailto:kwieser@intercell.com)

#### **About SSI**

Statens Serum Institut (SSI) is a Danish government-owned company engaged in the prevention and control of infectious diseases and congenital disorders. SSI is a manufacturer of vaccines and other biological products, approved by the US FDA, the European regulatory authorities, and the WHO. SSI is a major manufacturer of the current vaccine against Tuberculosis, the BCG vaccine. The TB research group at SSI is world-leading and has made important contributions to the understanding of TB infection and immunity. This research has recently resulted in improved diagnostic tools for TB as well as recombinant antigens for the development of improved TB vaccines.

For further information on Statens Serum Institut visit: [www.ssi.dk](http://www.ssi.dk)

#### **Contact SSI**

Pia Lading  
Executive Vice President  
Artillerivej 5 - DK-2300 Copenhagen S  
P: +45 3268 3565  
Mail to: [pla@ssi.dk](mailto:pla@ssi.dk)

#### **About Aeras Global TB Vaccine Foundation**

The Aeras Global TB Vaccine Foundation ([www.aeras.org](http://www.aeras.org)) is a non-profit organization working through public-private partnerships to develop new tuberculosis vaccines and ensure



that they are distributed to all who need them the world over. Aeras is supported primarily through the Bill & Melinda Gates Foundation. Prior to this, President & CEO Jerald C. Sadoff MD, led the research, development, and licensing efforts for numerous vaccines at Merck as well as the Walter Reed Army Institute of Research.

**Contact Aeras:**

Natalie Waugh  
Senior Director, External Affairs  
7500 Old Georgetown Road, Suite 800  
Bethesda, MD USA 20814  
P: +1 301-547-2917  
Email: [media@aeras.org](mailto:media@aeras.org)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*The information contained herein is not for publication or distribution in the United States of America. This press release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from Intercell AG and that will contain detailed information about the company and management, as well as financial statements.*